Le Lézard
Classified in: Health, Business
Subject: JVN

GVCL Ventures, Inc. Issues Shareholder Update


POMPANO BEACH, Fla., Oct. 18, 2017 /PRNewswire/ -- GVCL Ventures, Inc. (the "Company") (OTC: GVCL), today announces the termination of the Company's joint venture agreement (the "Joint Venture Agreement") with Pyramidion Technology Group, Inc. ("PYTG") and continues to pursue new business opportunities in a number of value enhanced industries.

The Company was not advised by PYTG of PYTG's termination of the Joint Venture Agreement until September 22, 2017.  However, management of the Company concurs with termination of the Joint Venture Agreement since PYTG's contribution to the joint venture was non-existent and its duties and obligations thereunder remained unfulfilled.  Management of the Company has determined the appropriate procedures for dissolution of the joint venture in accordance with the terms of the Joint Venture Agreement but to date, has had no response from PYTG to the Company's proposals.  Management will continue its efforts to ensure termination of the joint venture.

The Company also announces that it was flagged by the OTC Markets Group ("OTC Markets") for promotional activities and labelled with Caveat Emptor.  On September 11, 2017, the Company was advised by OTC Markets of unauthorized, third party promotional activities.  Neither the Company nor any of its affiliates solicited or paid for any investor relations or other third party reports.  The Company has been in communication with OTC Markets regarding this matter.  The Company confirms it is fully compliant with its current reporting requirements.  The Company further confirms it is not nor has been involved in any type of stock promotion activities.

About GVCL Ventures, Inc.:

GVCL Ventures, Inc. (www.gvclventures.com), is a business opportunity company with a focus on operational Cannabis, Hemp and CBD companies to work with for the purpose of enhancing shareholder value, in symphony with its wholly owned subsidiary, GVCL Marketing Corp., which provides a unique network marketing opportunity that utilizes its extensive access to online digital campaigns via the internet for its clients and partners, to enhance their productivity and revenue.

Forward Looking Statements
Undue reliance should not be placed on forward looking statements in this press release.  This press release contains forward looking statements that involve risks and uncertainties.  Words such as "will," "anticipates," "believes," "plans," "goal," "expects," "future," "intends," and similar expressions are used to identify these forward looking statements.  Actual results could materially differ from those anticipated in these forward looking statements for many reasons.

 

SOURCE GVCL Ventures, Inc.


These press releases may also interest you

at 03:00
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...



News published on and distributed by: